Sai Life Sciences IPO Prepares for Market Debut on December 11

Sai Life Sciences Limited, a key player in the pharmaceutical sector, is gearing up for its ₹3,042.62 crore Initial Public Offering (IPO). The offering comprises a fresh issue of ₹950 crores and an Offer for Sale (OFS) of ₹2,092.62 crores. The company is known for its expertise in research and small-molecule new chemical entity research and development, the company serves top global pharmaceutical firms with tailor-made solutions.

IPO Timeline and Business Overview

Sai Life Sciences Limited IPO opens for subscription on December 11, 2024, and closes on December 13, 2024. The allotment is expected to be finalizsed on December 16, 2024, with the listing scheduled on December 18, 2024, on BSE and NSE. The price band for the issue is set at ₹522 to ₹549 per share, with a minimum lot size of 27 shares requiring an investment of ₹14,823. Retail and non-institutional investors. Notably, 35% of the issue has been reserved for retail investors. 

The issue consists of ₹950 crores from fresh equity shares and ₹2,092.62 crores through an OFS. Leading firms such as Kotak Mahindra Capital, Jefferies India, Morgan Stanley India, and IIFL Securities are managing the issue, with Kfin Technologies acting as the registrar for the ₹3,042.62 crore issue of Sai Life Sciences Limited.

Business Overview

Incorporated in 1999, Sai Life Sciences Limited specializes in the research, development, and manufacturing of small-molecule new chemical entities. The company has a robust global footprint, providing services to over 280 pharmaceutical innovators, including 18 of the top 25 global pharma companies based on revenue in 2023. With a presence in major markets such as the US, UK, Europe, and Japan, Sai Life Sciences has established itself as a trusted partner in delivering tailored solutions to biotech and pharmaceutical firms.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.